YH12852

01/01/2021 - "We used the plasma concentrations of YH12852 from patients with functional constipation and healthy subjects and the GEBT results from healthy subjects obtained from a phase I/IIa trial. "
01/01/2021 - "YH12852 accelerated gastric emptying even at low doses of 0.05-0.1 mg, and its prokinetic effect was greater in subjects suffering from more severe functional constipation. "
01/01/2021 - "YH12852 can be developed as an effective treatment option for GI motility disorders, including functional constipation. "
01/01/2021 - "In addition, YH12852 increased quality of life satisfaction, and decreased severity of constipation symptom and GI symptoms. "
01/01/2018 - "YH12852 significantly improved both upper and lower bowel motility in the animal models tested and has the potential to address considerable unmet needs in patients with functional constipation, gastroparesis or both."

01/01/2018 - "YH12852 significantly improved both upper and lower bowel motility in the animal models tested and has the potential to address considerable unmet needs in patients with functional constipation, gastroparesis or both."

10/01/2017 - "YH12852, a potent and highly selective 5-HT4 receptor agonist, significantly improves both upper and lower gastrointestinal motility in a guinea pig model of postoperative ileus."